LLY – eli lilly and company (US:NASDAQ)
Stock Stats
News
12/4
04:25 pm
lly
Low
Eli Lilly and Company (NYSE:LLY) was upgraded by analysts at Weiss Ratings from a "hold (c+)" rating to a "buy (b-)" rating.
12/4
11:51 am
lly
Low
Eli Lilly and Company (LLY): A Bull Case Theory [Yahoo! Finance]
12/4
09:03 am
lly
Low
Eli Lilly and Company (NYSE:LLY) was given a new $1,200.00 price target on by analysts at BMO Capital Markets.
12/3
03:08 pm
lly
Low
Companies Cut Prices For Blockbuster Weight-Loss Drugs [Forbes]
12/3
02:08 pm
lly
Low
U.S. FDA approves expanded indication for Lilly's Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor [Yahoo! Finance]
10/30/2025
06:45 am
lly
-1.0%
BEAT
8/7/2025
06:45 am
lly
-1.6%
BEAT
5/1/2025
06:45 am
lly
-7.9%
MISS
2/6/2025
06:45 am
lly
4.9%
MISS
12/4
08:59 am
Maintains
Outperform
Outperform
BMO Capital
Low
-1.9%
12/4
08:59 am
Maintains
Outperform
Outperform
BMO Capital
Low
-1.9%
12/3
08:05 am
Reiterates
Buy
Buy
Guggenheim
Low
-1.2%
12/3
08:05 am
Reiterates
Buy
Buy
Guggenheim
Low
-1.2%
12/2
11:13 am
Reiterates
Outperform
Outperform
BMO Capital Markets
Low
-1.1%
11/26
04:00 pm
lly
Low
Form 4 ELI LILLY & Co For: Nov 25 Filed by: LILLY ENDOWMENT INC
11/26
04:00 pm
lly
Low
Form 4 ELI LILLY & Co For: Nov 25 Filed by: LILLY ENDOWMENT INC
11/25
04:00 pm
lly
Low
Form 4 ELI LILLY & Co For: Nov 24 Filed by: LILLY ENDOWMENT INC
11/24
04:00 pm
lly
Medium
Form 4 ELI LILLY & Co For: Nov 21 Filed by: LILLY ENDOWMENT INC
11/24
03:01 pm
lly
Low
Form 144 ELI LILLY & Co Filed by: LILLY ENDOWMENT INC
Show more
Top News Gainers
3/12 Eli Lilly, AbCellera Biologics to co-develop coronavirus therapies [Reuters] 14.2%
3/2 U.S. FDA Accepts Regulatory Submission for Tanezumab, a Potential First-in-Class Treatment for Patients with Chronic Pain Due to Moderate-to-Severe Osteoarthritis 5.8%
4/13 Despite Qualms, Arthritis Drug to Be Tested in Coronavirus Study [The New York Times] 4.6%
4/2 Eli Lilly And Co (NYSE: LLY) had its price target lowered by analysts at Morgan Stanley from $150.00 to $148.00. They now have an "overweight" rating on the stock. 4.2%
3/23 FDA enacts abbreviated approval pathway for insulin biosimilars [Seeking Alpha] 3.2%
4/16 Lower-priced versions of Humalog® Mix75/25™ KwikPen® and Humalog® Junior KwikPen® now available 3.2%
10/28 Insider Buying: The Eli Lilly and Company (NYSE:LLY) Chairman Just Bought US$500k Worth Of Shares [Yahoo! Finance News] 2.7%
2/4 Form 4 ELI LILLY & Co For: Feb 01 Filed by: Zulueta Alfonso G 2.7%
12/18 Lilly Announces the Launch of TRIUMPH, the First, Long-Term, Real-World Evidence Study of Emgality® (galcanezumab-gnlm) 2.7%
3/23 Lilly Provides Update on Clinical Trial Activities During COVID-19 Pandemic 2.6%
Top News Decliners
3/11 Eli Lilly to Participate in Program to Make Insulin Cheaper for Seniors [The Motley Fool] -10.0%
3/18 Hap Sneddon's Top Picks: March 18, 2020 [Business News Network (BNN) Energy & Resources (Canada)] -7.6%
3/20 Form DEFA14A ELI LILLY & Co -5.8%
7/11 New England Journal of Medicine Publishes Positive Phase 3 Data for Emgality® (galcanezumab-gnlm) in Episodic Cluster Headache -5.3%
6/9 Lilly's ultra rapid lispro provided similar A1C reductions compared to Humalog® (insulin lispro), with superior post-meal blood glucose reductions -4.0%
8/14 Lilly Launches Open Innovation Challenge to Help Transform Inflammatory Bowel Disease (IBD) Care through Digital Health -4.0%
4/28 Form 8-K ELI LILLY & Co For: Apr 24 -3.5%
2/27 Local Organization NOVA ScriptsCentral Benefits BIG with Eli Lilly release of Bulk Donation Insulin Pens -3.4%
2/21 Trulicity® (dulaglutide) is the first and only type 2 diabetes medicine approved to reduce cardiovascular events in adults with and without established cardiovascular disease -3.4%
8/5 Lilly Announces Positive Results for Emgality® (galcanezumab-gnlm) from the CONQUER Study in Patients who Failed Previous Migraine Preventive Treatments -3.4%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3